Literature DB >> 15448099

Selective loss of calcitonin gene-related Peptide-expressing primary sensory neurons of the a-cell phenotype in early experimental diabetes.

Yun Jiang1, Jens Randel Nyengaard, Jin Song Zhang, Johannes Jakobsen.   

Abstract

To evaluate the possible role of neuropeptide immunoreactive primary sensory neurons on the development of nociceptive dysfunction in diabetes, the absolute numbers of immunoreactive substance P and calcitonin gene-related peptide (CGRP) dorsal root ganglion (DRG) cell bodies were estimated in diabetic and nondiabetic BALB/C (p75(+/+)) and p75 receptor knockout (p75(-/-)) mice with unilateral sciatic nerve crush. The total numbers of immunoreactive substance P A-cells, substance P B-cells, CGRP A-cells, and CGRP B-cells in L5DRG were estimated using semithick consecutive sections and the optical fractionator. After 4 weeks of streptozotocin-induced diabetes, the number of immunoreactive CGRP A-cells was reduced from 692 +/- 122 to 489 +/- 125 (P = 0.004) in p75(+/+) mice on the noncrushed side. In p75(-/-) mice, there was no such effect of diabetes on the immunoreactive CGRP A-cell number. In p75(+/+) and p75(-/-) mice, there was no effect of diabetes on the immunoreactive CGRP B-cell number, nor was there any effect of diabetes on the immunoreactive substance P B-cell number. Sciatic nerve crush was associated with a substantial loss of L5DRG B-cells in diabetic and nondiabetic p75(+/+) mice and with substantial loss of immunoreactive substance P cells in diabetic p75(+/+) mice. In diabetic and nondiabetic p75(-/-) mice, there was no crush effect on neuropeptide expression. It is concluded that experimental diabetes in the mouse is associated with loss of immunoreactive CGRP primary sensory neurons of the A-cell phenotype, that this loss could play a role for the touch-evoked nociception in the model, and that the neuronal immunoreactive CGRP abnormality possibly is mediated by activation of the p75 neurotrophin receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448099     DOI: 10.2337/diabetes.53.10.2669

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain.

Authors:  Y Wang; M O Nowicki; X Wang; W D Arnold; S A Fernandez; X Mo; J Wechuk; D Krisky; J Goss; D Wolfe; P G Popovich; S Lawler; E A Chiocca
Journal:  Gene Ther       Date:  2012-12-13       Impact factor: 5.250

Review 2.  Medial arterial calcification in diabetes and its relationship to neuropathy.

Authors:  W J Jeffcoate; L M Rasmussen; L C Hofbauer; F L Game
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

Review 3.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 4.  Abnormal calcium homeostasis in peripheral neuropathies.

Authors:  Paul Fernyhough; Nigel A Calcutt
Journal:  Cell Calcium       Date:  2009-12-24       Impact factor: 6.817

5.  Exercise alleviates hypoalgesia and increases the level of calcitonin gene-related peptide in the dorsal horn of the spinal cord of diabetic rats.

Authors:  Patrícia Severo do Nascimento; Gisele Agustini Lovatel; Jocemar Ilha; Léder L Xavier; Beatriz D'Agord Schaan; Matilde Achaval
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

6.  Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications.

Authors:  David André Barrière; Christophe Noll; Geneviève Roussy; Farah Lizotte; Anissa Kessai; Karyn Kirby; Karine Belleville; Nicolas Beaudet; Jean-Michel Longpré; André C Carpentier; Pedro Geraldes; Philippe Sarret
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

7.  Remodelling of the intracardiac ganglia in diabetic Goto-Kakizaki rats: an anatomical study.

Authors:  Darius Batulevicius; Thomas Frese; Elmar Peschke; Dainius H Pauza; Vaida Batuleviciene
Journal:  Cardiovasc Diabetol       Date:  2013-06-07       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.